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ess: suleymansavash@ySummary Cytokines are known to be increased in induced sputum in chronic
obstructive pulmonary disease (COPD). In this study, the relationship between
the levels of interleukin-6 (IL-6), interleukin-8 (IL-8), and tumour necrosis factor-a
(TNF-a) in induced sputum of patients with exacerbation of COPD, and the severity
of the disease, pulmonary function tests (PFT), arterial blood gases (ABG) were
studied.
Twenty-four patients with exacerbation of COPD were included in the study. The
patients were grouped according to their PFT into two as: Group 1 (FEV1 below 50%
of the predicted value, severe–very severe COPD, n ¼ 12) and, Group 2 (FEV1 above
50% of the predicted value, mild–moderate COPD, n ¼ 12). The levels of IL-6, IL-8
and TNF-a in induced sputum of the subjects were measured.
The mean levels of IL-6, IL-8 and TNF-a in induced sputum were found to be
higher in Group 1 (severe–very severe COPD) than in Group 2 (mild–moderate COPD).
The differences in IL-6 and IL-8 levels between groups were statistically significant
(Po0:05). A significant correlation was observed between the IL-6 value and FEV1
(r ¼ 0:435, P ¼ 0:034), FEV1/FVC (r ¼ 0:446, P ¼ 0:029), PaO2 (r ¼ 0:711,
P ¼ 0:000), SaO2 (r ¼ 0:444, P ¼ 0:030) and disease duration (r ¼ 0:427,
P ¼ 0:037), respectively. Also, the level of IL-8 in induced sputum was inversely
correlated with FEV1 (r ¼ 0:562, P ¼ 0:004), PaO2 (r ¼ 0:540, P ¼ 0:006) and SaO2
(r ¼ 0:435, P ¼ 0:034). However, all three cytokines were positively correlated
with the smoking load (r ¼ 0:653, P ¼ 0:001; r ¼ 0:439, P ¼ 0:032; r ¼ 0:649,
P ¼ 0:001).
We conclude, therefore, that in exacerbated COPD cases with greater degrees of
obstruction of the airways have higher levels of cytokines in induced sputum. ThisElsevier Ltd. All rights reserved.
2341 0660.
ahoo.com (S.S. Hacievliyagil).
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parameters like the ABG and PFT and seem to be the determinant of the severity of
the disease.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is an
important lung disease characterized by progres-
sive airway obstruction due to chronic inflamma-
tion.1 Exacerbations in COPD lead to increases in
the number of patients reporting to the hospital
and the frequency of admissions. It also affects
adversely the quality of life of the patients and
restricts their daily activities.2 COPD exacerbations
are responsible for the increase in morbidity and
mortality rates attributable to the disease.3
Cytokines are extracelluler signal proteins less
than 80 kDa formed by various cell types in the
body. Interleukin-6 (IL-6) is secreted by monocytes,
macrophages, T cells, B cells, fibroblasts, epithelial
cells of the airways and endothelial cells. Under the
activation of IL-1b and TGF-b, IL-6 is secreted from
the smooth muscles of the airways. IL-6 are
pleotrophic cytokines with a role in the activation,
proliferation and differentiation of T cells. IL-6 also
serves as a terminal differentiating factor for B
cells, and induces immunoglobins like IgG, IgA and
IgM.4 Interleukin-8 (IL-8), also known as CXCL8, is a
CXC chemokine that is a potent chemoattractant
for neutrophils. In general, monocytes, tissue and
alveolar macrophages, pulmonary epithelium, cells
of the smooth muscles of the airways, eosinophils,
fibroblasts, and endothelial cells are its important
sources.5 Tumour necrosis factor-a (TNF-a) is
produced from several cells including T lympho-
cytes, mast cells and cells of the airway epithe-
lium. TNF-a controls cellular migration and
permeability and also stimulates the secretion of
GM-CSF, IL-6 and IL-8. It also activates the
transcription factor-kB (NF-kB) which in turn
activates the IL-8 gene in epithelial cells and
macrophages.6
The role inflammation and the cytokines play in
the pathogenesis of COPD have attracted more
interest in recent times.4,6,7 In COPD patients
elevation of cytokine levels are known to be even
more apparent during exacerbations. This situation
has been demonstrated by the presence of inflam-
matory cells and elevated levels of the cytokines in
the serum, induced sputum, bronchoalveolar la-
vage (BAL) fluid and bronchoscopic biopsy speci-
mens.8–11 Aaron et al.12 studied the levels of IL-8
and TNF-a in induced sputum among COPD patientsduring their stable periods, at exacerbation and
during the stable period a month after the
exacerbation episode. The levels of IL-8 and TNF-
a in induced sputum were observed to be higher in
the exacerbation period than in the stable period,
falling again during the stable period a month
afterwards.
Many cytokines are increased or activated in
COPD, but their contribution to disease severity is
still unknown. In this study, the relationship
between the levels of IL-6, IL-8 and TNF-a in
induced sputum and the severity of the disease,
pulmonary function tests (PFT), arterial blood
gases (ABG) were investigated.Materials and method
A total of 30 male COPD patients reporting to the
pulmonary diseases clinic of the Turgut Ozal
Medical Center, Inonu University, (Malatya, Turkey)
with exacerbation of disease were enrolled. Diag-
nosis of COPD was made based on the American
Thoracic Society and European Respiratory Society
criteria,13 with exacerbation identified according
to the definition by Anthonisen et al. which is based
on an increase in symptoms of dyspnoea, sputum
volume and sputum purulence with or without
symptoms of upper respiratory infection and then
subdivided depending on the number of symptoms.
All patients with COPD exacerbation in our study
have all major exacerbation symptoms (type I
exacerbation).14
The patients had no other pulmonary disease
including asthma, bronchiectasia, pneumonia, tu-
berculosis or lung cancer. All subjects were hospi-
talized because of type I exacerbation of COPD and
they were no medications except for COPD. Each
patient was given a brief explanation about the
study and their consent for voluntary participation
obtained. The clinical history of each patient was
obtained after which a through physical examina-
tion was conducted. Routine laboratory analysis,
echocardiography and radiologic studies were or-
dered. PFTwere performed in all cases by using the
Vmax 22 device (SensorMedics Ltd., Yorba Linda,
CA, USA) and ABG conducted for each patient
breathing room air. A total of six patients were
excluded from the study for various reasons: one
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due to development of bronchospasm during the
induction stage for sputum, and for withdrawal of
consent by another three patients. Therefore 24
patients therefore completed the study.
The subjects were classified into two groups
based on their FEV1 results. Those with an FEV1
below 50% of the predicted value were placed in
Group 1 (severe–very severe COPD, n ¼ 12), while
those with FEV1 above 50% of the predicted value
formed Group 2 (mild–moderate COPD, n ¼ 12).
Before the commencement of the treatment for
the exacerbation induced sputum samples were
taken from patients by ultrasonic nebulizators
(Hirtz, Hico-Ultrasonat 806 EH, Ko¨ln-Germany).
For this purpose, patients were made to rinse their
mouths with water after inhalation of a 3% saline
solution for 5–7min and then asked to expectorate
deeply for the 2ml induced sputum samples to be
collected. In patients in whom adequate amount of
sample could not be collected saline inhalation was
repeated at the same dose and subsequently
increased (at a concentration of 4.5%).15 The
samples that were collected into a wide-coveredTable 1 Basic properties and laboratory values of patien
Group 1 (FEV1o
Subjects, n 12
Age (years) 59.3711.7
Duration of disease (years) 13.877.7
Smoking load (pack-years) 41.4721.1
Smoking status (yes/ex/never) 7/5/0
IL-6 (pg/ml) 697.87662.8
IL-8 (pg/ml) 10054.372330.2
TNF-a (pg/ml) 134.67140.7
FVC (% predicted) 63.5718.8
FEV1 (% predicted) 33.879.7
FEV1/FVC (%) 43.779.1
FEF25%–75% 13.374.9
PH 7.3970.8
PaO2 (mmHg) 45.877.1
PaCO2 (mmHg) 44.077.4
SaO2 (%) 79.679.2
HCO3
 (mmol/l) 29.077.0
Hemoglobin (g/dl) 15.172.4
Hematocrit (%) 47.178.2
BUN (mg/dl) 22.8713.6
Leukocyte count (109/l) 12366.775261.4
Creatinine (mg/dl) 1.070.3
Albumin (mg/dl) 2.670.2
PAPs (mmHg) 38.6725.9
Data presented as mean7SD (standard deviation) or n, unless oth
tumor necrosis factor-a, FVC: forced vital capacity, FEV1: forced
flow, pH: arterial blood pH, PaO2: arterial oxygen tension, PaC
saturation, HCO3
: arterial bicarbonate, BUN: blood urea nitrojen,sterile 50 cc polypropylene plastic cups were
immediately transferred to the laboratory after
labelling for processing. The induced sputum
samples were analysed within an hour. The sputum
samples were prevented from contamination by
saliva by filtering through a double-layered sterile
gauze immediately after collection. With the aid of
a forceps and spatula approximately 1–1.5 g was
taken from each sample and transferred into 10ml
sterile polypropylene tubes with predetermined
weights and reweighed. After the addition of a
phosphate buffer solution (PBS) that weighed nine
times their fresh weight 5–6 pieces of silicone glass
beads were introduced into each tube and stirred
with a vortex for 10min until a homogenized
solution was obtained. The solution was thereafter
subjected to centrifugation at +4 1C for 10min at
1000g. The resulting supernatant was transported
into polypropylene tubes in aliquots of 1ml. After
the addition of 10 ml 100mM phenyl methyl sulfonyl
fluoride (PMSF) into each tube they were covered
and turned upside down several times to ensure
adequate mixing. Until analysed they were stored
at 70 1C.16ts in Groups 1 and 2.
50%) Group 2 (FEV1450%) P value
12
59.879.3 NS
13.377.0 NS
28.6714.0 NS
8/4/0 NS
216.17350.8 0.037
7159.372973.2 0.014
96.37158.1 NS
90.9720.9 0.003
61.9718.8 0.000
50.079.7 NS
27.8715.1 0.005
7.4570.4 0.04
52.676.2 0.021
40.878.5 NS
85.776.2 0.002
30.175.4 NS
15.471.3 NS
47.975.6 NS
18.4710.4 NS
9375.073252.7 NS
0.870.2 NS
3.270.5 NS
30.6719.6 NS
erwise stated. IL-6: interleukin-6, IL-8: interleukin-8, TNF-a:
expiratory volume in 1 s, FEF25%–75%: forced mid-expiratory
O2: arterial carbon dioxide tension, SaO2: arterial oxygen
PAPs: systolic pulmonary artery pressure), NS: not significant.
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chemiluminiscence method using an Immulite-1000
analyzer and special kits (DPC [Diagnostic Product
Co., CA, USA]). The lower limit of detection for
these assays was 5 pg/ml for IL-6, 2 pg/ml for IL-8
and 5 pg/ml for TNF-a. The inter- and intra-assay
coefficient of variation of these all assays was less
than 10%. The samples which were higher than
detection limits of cytokines were reanalysed with
a dilution of 0.9% serum saline solution for one
times weight.
The patients were compared for demographic
and laboratory parameters of subjects. The data
obtained were analysed with the SPSS version 10.0
(Chicago, IL, USA) statistical program. Data are
expressed as means and standart deviation. Differ-
ences between groups were analysed using Stu-
dent’s t-test. Correlations between different
parameters were evaluated using the Pearson’s
correlation test. The significance level was con-
sidered as Po0:05.Results
The demographic properties and laboratory values
of the subjects in Groups 1 and 2 are shown in
Table 1. The differences of values of FVC, FEV1,
FEF25%–75%, pH, PaO2 and SaO2 between groups
revealed statistically significant (Po0:05). The
average induced sputum IL-6 level for Groups 1
and 2 was 697.87662.8 and 216.17350.8 pg/ml,
respectively (P ¼ 0:037). The level of IL-8 in
the induced sputum was 10054.372330.2 pg/ml
for Group 1 and 7159.372973.2 pg/ml for Group 2
(P ¼ 0:014). The levels of TNF-a in induced sputum
were found to be 134.67140.7 and 96.37158.1 pg/
ml for Groups 1 and 2, respectively. No statistically
significant difference was observed between the
groups in the TNF-a levels (P40:05).
As shown in Fig. 1a and b, the levels of IL-6
and IL-8 in induced sputum correlated negatively
with FEV1 (r ¼ 0:435, P ¼ 0:034; r ¼ 0:562, P ¼
0:004). In addition, the levels of IL-6 in induced
sputum significantly correlated, respectively, with
FEV1/FVC (r ¼ 0:446, P ¼ 0:029, Fig. 1c) and
disease duration (r ¼ 0:427, P ¼ 0:037, Fig. 1d).
Also, the levels of IL-6 and IL-8 in induced sputum
correlated negatively with PaO2 (r ¼ 0:711, P ¼
0:000, Fig. 1e; r ¼ 0:540, P ¼ 0:006, Fig. 1f) and
SaO2 (r ¼ 0:444, P ¼ 0:030, Fig. 1g; r ¼ 0:435,
P ¼ 0:034, Fig. 1(h). However, there was a sig-
nificant correlation between levels of all three
cytokines and smoking load (pack-years) (r ¼ 0:653,
P ¼ 0:001; r ¼ 0:439, P ¼ 0:032; r ¼ 0:649, P ¼
0:001, Fig. 2).Discussion
In COPD there is a chronic inflammatory process
within the airways that increases during an acute
episode.1,6 The induced sputum method, a non-
invasive method adequate enough in demonstrating
inflammation in the airways such as that occuring in
COPD has been shown in earlier studies to be a
reliable method.15–18 In our study, the cytokine
levels in patients with exacerbation of COPD have
been found to relate to the PFT, ABG, as well as to
the severity of disease.
Keatings et al.19 found high IL-8 levels in induced
sputum of COPD patients. In another study,
Yamamoto et al.20 found higher IL-8 levels in the
sputum of COPD patients than that in asthmatic
patients and normal controls. In their study,
Vernooy et al.21 found higher induced sputum IL-8
levels in 18 COPD patients compared to their 17
smoking control subjects. Keatings et al.19 and
Yamamoto et al.20 demonstrated a positive correla-
tion between the IL-8 level and the neutrophil
proportions. This could not be verified in our study
because characterization of cellular components of
the sputum was not performed. On the other hand,
all patients in this study had all the major
symptoms of exacerbations as an increase in
symptoms of dyspnoea, sputum volume and sputum
purulence (type I exacerbation).14,22 Gompertz et
al.23 suggest that exacerbations of COPD defined by
sputum colour, differ in the degree of bronchial and
systemic inflammation. They found purulent ex-
acerbations were associated with marked bronchial
and systemic inflammation and bacterial infection.
Another lacks of present study, the bacteriology or
viral cultures of sputum was not processed, so this
papers is not given any information about levels of
airway inflammation and bacterial infections or
colonizations. We found the cytokines levels in the
induced sputum more higher in severe or very
severe COPD patients than mild or moderate COPD
patients. It has been suggested that these cytokines
play a role in airway inflammation and severity of
disease.
With each episode of exacerbation there is
gradual deterioration in the respiratory functions
of the patient. In those patients with frequent
exacerbations the fall in FEV1 is much greater than
it is in those with less frequent exacerbations.24
Frequent exacerbations increase the severity of the
respiratory tract inflammation. Bhowmik et al.8
found that the levels of IL-6 and IL-8 in induced
sputum of patients with three or more episodes per
year were higher than those with less frequent
attacks. In contrast, Gompertz et al.25 found no
significant differences between those with three or
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with less attacks. Soler et al.26 demonstrated a
negative correlation between the FEV1 and the IL-6
and IL-8 levels in BAL fluid. In contrast to these
studies, however, Bhowmik et al.8 failed to estab-
lish any relationship between the induced sputum
IL-6 and IL-8 levels and the PFT parameters and the
time for improvement in symptoms and PEF valuesFEV1
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Figure 1 Correlations between (a) the levels of IL-6 and FEV
(r ¼ 0:562, P ¼ 0:004); (c) the levels of IL-6 and FEV1/FVC (
duration (r ¼ 0:427, P ¼ 0:037); (e) the levels of IL-6 and PaO
(r ¼ 0:540, P ¼ 0:006); (g) the levels of IL-6 and SaO2 (r
(r ¼ 0:435, P ¼ 0:034).in the exacerbation period. Yamamoto et al.20
reported a negative correlation between the IL-8
levels in induced sputum and the FEV1/FVC ratio in
COPD. Similarly we found a negative correlation
between the levels of IL-6 in induced sputum and
FEV1/FVC ratios in this study. Also, FEV1 of the
predicted value was inversely correlated with the
levels of IL-6 and IL-8 in induced sputum, but notFEV1
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1 (r ¼ 0:435, P ¼ 0:034); (b) the levels of IL-8 and FEV1
r ¼ 0:446, P ¼ 0:029); (d) the levels of IL-6 and disease
2 (r ¼ 0:711, P ¼ 0:000); (f) the levels of IL-8 and PaO2
¼ 0:444, P ¼ 0:030); (h) the levels of IL-8 and SaO2
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Figure 1 (Continued)
Association between cytokines in induced and severity of COPD 851TNF-a levels. This indicates that the levels of IL-6
and IL-8 in induced sputum might be related to the
severity of the respiratory tract obstruction. And
we think that presence of high levels of cytokines in
induced sputum increases inflammation in the
airways that in turn increases the susceptibility to
exacerbations.
With hypoxia IL-6 and IL-8 are secreted from the
endothelial cells.27,28 In addition, hypoxia is
thought to be related to activation of the TNF-a
system in COPD patients.29 Yasuda et al.30 found
that although the difference was not statistically
significant, the TNF-a and IL-6 levels among severeCOPD patients with hypoxemia was higher than
their non-hypoxic controls who had mild–moderate
COPD. We found severe and very severe patients
who are more hypoxemic patients had higher
cytokines levels. However, there was a relation
between the levels of IL-6 in induced sputum and
hypoxemia, might due to increased inflammation
associated with hypoxemia.
Cigarette smoking is the most important cause of
COPD. However, some smokers develop COPD and
the reason is still unknown.1 Bhowmik et al.8
established a correlation between the levels of IL-
6 and IL-8 in induced sputum and the pack-years of
ARTICLE IN PRESS
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Figure 2 Correlations between (a) the levels of IL-6 and smoking load (pack-years) (r ¼ 0:653, P ¼ 0:001); (b) between
the levels of IL-8 and smoking load (pack-years) (r ¼ 0:439, P ¼ 0:032); (c) between the levels of TNF-a and smoking
load (pack-years) (r ¼ 0:649, P ¼ 0:001).
S.S. Hacievliyagil et al.852cigarettes smoked. Wang et al.31 measured the
levels of IL-6 and IL-8 in induced sputum in 20
stable COPD patients and compared them with
smoking and non-smoking control groups. The IL-8
and TNF-a levels in the COPD group were found to
be significantly higher than the smoking and non-
smoking groups with the IL-8 level in the smoking
group also significantly higher than the non-smok-ing group. The IL-6 levels, however, did not show
any significant differences between the groups. In
our study a positive correlation was established
between the levels of all three cytokines and the
smoking load (pack-years). This indicates that
higher smoking load had higher cytokine levels in
their induced sputum. The initiation of cytokines
release in COPD is likely to be due to the direct
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lighted a close link between smoking and levels
of cytokines in induced sputum and therefore
smoking needs to be prevented. On the other hand,
correlations examined in induced sputum suggest
that those patients with a longer history of disease
duration had higher cytokines levels. For the
determination of disease duration, we used the
date of first visit to a doctor for chronic complaints
of cough, dyspnea and sputum production.
We therefore conclude that, in our study, COPD
patients with more marked obstruction had higher
IL-6, IL-8 and TNF-a levels in their induced sputum
samples. In addition to its determinant role in the
pathogenesis of COPD the levels of IL-6 and IL-8 in
induced sputum were found to be directly related
to the ABG and PFT, parameters that determine the
severity of disease. The airway inflammation in
those patients with higher cytokine levels increased
leading to an increase in the rate of exacerbations.
Reducing the rate of exacerbation episodes in COPD
will no doubt result in a marked fall in the
morbidity and mortality of the disease. Current
treatment is centered on the use of bronchodila-
tors. As the importance of inflammation in the
pathogenesis of COPD emerges treatment of COPD,
just as in asthma will definitely be geared toward
the control of inflammation. By contrast, the
inflammatory process in COPD appears to be
resistant to corticosteroids, indicating that new
anti-inflammatory treatments will be needed. It is
our opinion, therefore, that anti-cytokine agents to
be developed will be an important leap forward in
the prevention of COPD and its progression as well
as minimalizing severity of disease.Acknowledgements
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